A well-tolerated topical retinoid, tazarotene, has recently been introduced for mild to moderate psoriasis.
In addition, tazarotene (Tazorac), a drug approved by the United States Food and Drug Administration (FDA) in 1997, is proving to be effective for mild-to-moderate plaque psoriasis.
Tazarotene, sold under the brand name Tazorac.